

What: Operations Committee Meeting  
When: April 25, 2023; 12:30-1:30 p.m. PT  
Where: Zoom Meeting

To register for the meeting, please review the [Public Comment Protocol](#) then email [wvameetings@wavaccine.org](mailto:wvameetings@wavaccine.org) at least two business days in advance of the meeting.

***WVA Agendas are subject to revision up to and including the time of the meeting.***

Notice: The meeting may be recorded for the benefit of the minute-taker.  
The WVA intends to delete the recording after the minutes are approved.

### Agenda for Operations Committee Meeting

Approx. Time	Page		Topic/[Anticipated Action]	Presented by:
12:30-12:35 p.m.			1. Introductions & Agenda Review a. Notice of Recording b. Survey of Other Topics	J. Zell
12:35-12:40 p.m.	Pg. 3-5	*	2. Action Items a. Operations Committee Minutes (October 27, 2022)	J. Zell
12:50-1:20 p.m.	Pg. 6-16 Pg. 17-25	* *	3. Assessment Grid 2023-24 a. Process and Communications Plan b. Vote - Assessment Grid 2023-24	J. Zell / P. Miller
12:40-12:50 p.m.	Pg. 26-27	*	4. Operations Updates a. Provider Compliance and Performance Improvement Plan Discussion b. Payer Compliance c. New Vaccine Preview	J. Zell / P. Miller  J. Jorgenson
1:20-1:30 p.m.			4. Other Matters from Committee Members	Any
1:30 p.m.			5. Closing	J. Zell

**\*Indicates Agenda Item Attached**

**April 25, 2023**

**WVA Meeting of the Operations Committee**

**Proposed Form of Votes**

The following are suggested forms of votes only. They are intended to be an aid to facilitate work by individual directors and committee members.

**Items under Agenda Section 2:**

VOTED: To approve October 27, 2022 meeting minutes.

[To approved October 27, 2022 meeting with the changes suggested at the meeting.]

**Items under Agenda Section 3:**

VOTED: To approve the July 1, 2023 Vaccine Assessment Grid.

[To approve the July 1, 2023 with the changes suggested at the meeting.]

**Washington Vaccine Association  
Operations Committee Meeting  
October 27, 2022; 12:30-1:30 p.m. PT**

**I. Attendance.** Participating in all or part of the meeting by telephone were the following individuals:

<u>Members</u>	<u>WVA</u>
Walter Kuice, Regence	Julia G. Zell, Esq., Executive Director, Chair
Jennifer Simonsen, Kaiser	
Tracey Cardillo, Cigna	<u>Helms &amp; Company, Inc.</u>
Sue Bride, Premiera	Patrick Miller, MPH, Administrative Director
Cathy Falanga, Aetna	Ashley Ithal, MPH, Project Support Leader
Nicole Carroll, UnitedHealthcare	
Janel Jorgenson, DOH	<u>Public Members</u>
	Breelynn Young, GSK

**I. Summary of Actions Taken and/or Recommended**

Actions Taken (votes adopted)

- i. To approve April 28, 2022, meeting minutes.
- ii. To approve the addition of any pediatric COVID vaccine added to the Washington Childhood Vaccination Program to the WVA Assessment Grid at a blended price, TBD.
- iii. To approve the addition of Priorix and Vaxneuvance to the WVA Assessment Grid when it is added to the Washington Childhood Vaccination Program at 2% above the CDC contract price.

**II. Welcome and Introductions**

At 12:34 p.m., Ms. Zell called the meeting to order and provided a notice of recording. Mr. Miller introduced the attending staff members from Helms.

**III. Calendar Consent Items**

Ms. Zell asked for a motion to approve the April 28, 2022, meeting minutes. There being no other questions or comments, the following item was put to a vote:

Upon motion duly made and seconded, it was unanimously

**VOTED: To approve April 28, 2022, meeting minutes.**

**IV. Operations Updates**

Provider Compliance

Ms. Zell reminded the group that the WVA has taken on new provider outreach and compliance efforts this year as historically the WVA has not had a direct relationship with providers. It has become more apparent that outreach and relationship building with the providers can address non-compliance issues in a proactive manner. New provider education materials have been created, including a checklist that is designed to prevent common and systematic errors. Ms. Zell let the group know that a provider liaison will be hired by the WVA in the spring of 2023. The goal of this position is to assist the WVA in its efforts to create partnerships and prevent upstream errors.

Payer Compliance

Ms. Zell updated the group that a policy regarding collection of past due DBAs will be reviewed at the November 2022 Board meeting. There are both payer and provider generated issues with regards to Vaccine Grid adherence, denials, and patient responsibility that result in denials or delayed payments. The drafted policy states that if the issue at hand stems from a provider generated issue, then the WVA will generally only look back for a one-year period. If the issue at hand stems from a payer generated issue, then the WVA will generally limit the look back period for five years.

#### Vaccine Grid 2023/24

Ms. Zell reminded the group that the Grid amounts have remained steady for the past three years, with the WVA absorbing CDC vaccine price inflation. It is expected that the 2023/24 grid will increase overall due to increased funding requests from the Department of Health driven by both utilization and CDC pricing.

#### Fund Source Split

Ms. Zell reminded the group that the fund source split describes the proportion of vaccine costs that are allocated by the Department of Health (DOH) to the WVA versus the Childhood Vaccine Program (CVP). The WVA's portion of the allocation will be increasing in January 2023. Mr. Miller added that the fund source split is not recalculated on a regular basis and the WVA needs to incorporate the new split into the WVA's financial model for budgeting purposes. This new split is also part of the expected increase in the 2023/24 Vaccine Grid.

### **V. COVID Planning**

Ms. Zell provided an overview of WVA planning for assumed discontinuation of Federal funding for COVID vaccines in the second quarter of 2023. The date has not been formally communicated yet but stems from discussions that the DOH has had with the CDC in recent months. The WVA team will use a communications plan created for the off-cycle Vaccine Grid additions of Priorix and Vaxneuvance to guide the COVID vaccine grid additions. This model includes a timeline for vaccine rollout, votes to approve the off-cycle Vaccine Grid changes by the WVA Operations Committee and Board of Directors, and a DOH/WVA co-developed communication plan to payers and providers.

Ms. Zell stated that the current plan is to develop a single, blended amount for all COVID vaccines, at least until the next Vaccine Grid update effective July 1, 2023. At the moment, the CDC has not added the COVID vaccines to their price list, so we are currently unsure of what the financial impact will be. Mr. Miller stated that vaccine hesitance is also impacting uptake in some of the children age groups which also needs to be considered in the financial models the DOH will create to drive their funding requests of the WVA. There was further discussion from members of the Committee regarding the potential impacts of the COVID vaccine additions, including impacts to the Vaccine Grid, the 60-day payer notification requirement, education of payers and providers, and compliance.

Ms. Zell asked for a motion to approve the addition of any pediatric COVID vaccine added to the Washington Childhood Vaccination Program to the WVA Assessment Grid at a blended price, TBD. There being no other questions or comments, the following item was put to a vote:

Upon motion duly made and seconded, it was unanimously

**VOTED: To approve the addition of any pediatric COVID vaccine added to the Washington Childhood Vaccination Program to the WVA Assessment Grid at a blended price, TBD.**

Ms. Zell stated that in addition to the expected COVID vaccines, that there are two, new vaccines expected to be added to the CDC's price list later this year: Priorix and Vaxneuvance. Currently, it is unclear when these two vaccines will be added by the CDC, when they will be available within the DOH's order set to providers, and when DBA billing will commence. There is still the same 60-day payer notification requirement as previously mentioned during the COVID discussion. Ms. Zell stated that there is an expectation that several additional vaccines will be coming to market in the next few years, so developing a process to address these off-cycle vaccine additions is imperative.

Ms. Zell asked for a motion to approve the addition of Priorix and Vaxneuvance to the WVA Assessment Grid when they are added to the Washington Childhood Vaccination Program at 2% above the CDC contract price. There being no other questions or comments, the following item was put to a vote:

Upon motion duly made and seconded, it was unanimously

**VOTED: To approve the addition of Priorix and Vaxneuvance to the WVA Assessment Grid when they are added to the Washington Childhood Vaccination Program at 2% above the CDC contract price.**

#### **VI. Closing**

Ms. Zell thanked everyone for their input and guidance today, and the meeting was adjourned at 1:27 pm PT.




*Ensuring Funds for Childhood Vaccines*

## 2023-24 Vaccine Assessment Grid

Presented to the  
Washington Vaccine Association  
Operations Committee Meeting  
April 25, 2023

Confidential and Proprietary © 2023




Meeting Packet Page 6

# Presentation Overview

1. Process Timeline
2. Integrated Approach
3. Model
4. Grid Communications and Compliance
5. 2023-24 Grid (Attachment)




# 1. 2023-24 Budget & Vaccine Grid Development Process






## 2. Integrated Approach


1. There is a nested relationship between the administrative budget, the cash flow model, and the vaccine assessment grid
2. Goals of the 2023-24 vaccine grid process include:
  1. Providing grid stability to minimize year-to-year fluctuation
  2. Maintain cash and reserves to a Board-approved level
  3. Ensure reserves for COVID and other new vaccines



### 3.i. Model: Weighted CDC Contract Price Increases (specific to WVA's utilization)



## 3.ii. Model: Historical and Model Projections End of FY Cash Balance – FY2017-25




# 3.iii. Model: FY2024 Notable Projection Assumptions

- Fund Source Split Adjusted CY2023
  - 47% WVA; 50% VFC; 3% CHIP
- Changing Presentations
  - Menveo (MCV40)
  - Rotarix (RV1)
- New Vaccines
  - Priorix (MMR)
  - Vaxneuvance™ (PCV15)
  - Prevnar 20® (PCV20)
- New Vaccines in Pipeline
  - RSV (Date Unknown)
- Pandemic Impact on Vaccine Utilization
  - Provider Enrollment Has Outpaced Disenrollment; Enrollment Down Nearly 4% Since July 2021
- Provider Order Levels are Below Pre-Pandemic Levels; Have Recently Increased and Expected To Increase 2% in FY2024 Over FY2023
- COVID Vaccines
  - Expect Fall / Late Fall 2023 Commercialization
  - Vaccine Presentation Options Uncertain; Expected to Change in Coming Years
  - VFC Pricing Estimated at \$80-100/dose
  - WVA Portion Estimated to be \$1.7M in FY24 and \$2.1M in FY25
  - Prebuy Process is Possible
  - New VFC Providers Anticipated
  - Retail Pharmacy Role Likely

### 3.iv. Model: Assumptions Summary

Adjustment Variables	Assumptions			
	FY2023	FY2024	FY2025	FY2026
Assessment Grid as Percent of Prior Year	100%	110%	110%	110%
TRICARE Surcharge (3-Year Lock)	2.5%	2.5%	2.5%	2.5%
DOH Indirect Charge	1.4%	1.4%	1.4%	1.4%
DOH Cost Recovery Fee (2.8% Cap)	1.4%	1.4%	1.4%	1.4%
Vaccine Wastage	2.7%	2.5%	2.4%	2.4%
Denials	13.0%	7.0%	6.0%	5.0%
Denial Recoveries	4.0%	1.0%	1.0%	1.0%
Administrative Budget	\$2.07M	\$2.19M	\$2.26M	\$2.33M
Cash “Burn Down” Amount	(\$11.3M)	\$10.6M	\$3.3M	(\$2.3M)
Year End Balance	(\$43.6M)	\$33.0M	\$29.7M	\$32.0M
CDC Vaccine Purchase Price Increase	3.6%	4.6%	3.9%	3.5%

### 3.v. Model: Weighted Average Grid Amount Vs. Weighted Average Private Sector Price – FY2017-24



# 4. Grid Communications and Compliance



Initiator / Audience	May	June	July	August-September
Provider Notification	Email	Email Reminder Physical Mailing		
Payer Notification	Email Physical Mailing	Email Reminder		
Other Stakeholder Notification	Email Physical Mailing	OneHealthPort Updates Website		
Prevnar 20 Updates				Tentative Timeframe
Grid Compliance			Payer Notification	Payer Notification



Initiator / Audience	May	June	July	August-September
Provider Notification	Email	Email Reminder	Email Reminder	



# 5. 2022-23 Vaccine Grid



## 2023-24 Vaccine Assessment Grid

Washington Vaccine Association Assessment Grid

FOR ALL CLAIMS WITH A DATE OF SERVICE ON OR AFTER JULY 1, 2023.

For Dosage-Based Assessment (DBA) Billing Used for Commercially Insured Patients Under the Age of 19.

Please note that this **WVA Assessment Grid**, effective July 1, 2023, replaces the grid last updated on July 1, 2022. The grid lists vaccines and their corresponding CPT codes that are part of the dosage-based assessment (DBA) process for providers, health insurance carriers, and third party administrators. There are other childhood vaccines (and corresponding CPT codes) that are not included in the DBA process and, therefore, no assessment is needed. The availability of specific vaccine brands are determined by the manufacturer and not all brands of flu vaccine are offered through the Childhood Vaccine Program (CVP). **The PURPLE COLUMN is the assessment amount per dose as of July 1, 2023.**

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose from 07/01/2022 to 06/30/2023	For Reference: CDC Private Sector Cost/Dose 04/01/2023	WVA Assessment Amount per dose from 07/01/2023 to 06/30/2024	Percent Change 07/01/2022 to 07/01/2023
Hepatitis A							
90633	58160-0825-52 (10 pack – 1 dose syringe)	Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use	Havrix®	\$20.72	\$36.92	\$22.79	10.0%
	00006-4095-02 (10 pack – 1 dose syringe)		Vaqta®		\$36.66		
Hepatitis B							
90744	00006-4981-00 (10 pack – 1 dose vial)	Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use	Recombivax HB®	\$12.54	\$26.35	\$13.79	10.0%
	00006-4093-02 (10 pack – 1 dose syringe)						
	58160-0820-52 (10 pack – 1 dose syringe)		Engerix B®		\$27.36		
Rotavirus							
90680	00006-4047-41 (10 pack – 1 dose tube) <b>ADDED: 00006-4047-20 (25 pack – 1 oral dose)</b>	Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use	RotaTeq®	\$72.04	\$93.19	\$79.24	10.0%
90681	58160-0854-52 (10 pack – 1 dose vial)	Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use	Rotarix®	\$97.88	\$134.72	\$107.67	10.0%
	58160-0740-21 (10 pack – 1 oral dose)				\$130.82		

Page 1

This document is available in PDF and Excel versions at: <https://wavaccine.org/assessment-grid/>

**APPROVED April 25, 2023  
EFFECTIVE July 1, 2023**

For Vote by  
Operations  
Committee.

New: Sorted by  
Vaccine  
Category.

New: Excel  
Version Adds  
Tabs With  
Sortable  
Columns.

Includes Price for  
Pevnar 20.  
Expect Fall 2023  
Availability.

## Washington Vaccine Association Assessment Grid

**FOR ALL CLAIMS WITH A DATE OF SERVICE ON OR AFTER JULY 1, 2023.**

**For Dosage-Based Assessment (DBA) Billing Used for  
Commercially Insured Patients Under the Age of 19.**

Please note that this **WVA Assessment Grid, effective July 1, 2023, replaces the grid last updated on July 1, 2022.** The grid lists vaccines and their corresponding CPT codes that are part of the dosage-based assessment (DBA) process for providers, health insurance carriers, and third party administrators. There are other childhood vaccines (and corresponding CPT codes) that are not included in the DBA process and, therefore, no assessment is needed. The availability of specific vaccine brands are determined by the manufacturer and not all brands of flu vaccine are offered through the Childhood Vaccine Program (CVP). **The PURPLE COLUMN is the assessment amount per dose as of July 1, 2023.**

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount <u>per dose</u> from 07/01/2022 to 06/30/2023	For Reference: CDC Private Sector Cost/Dose 04/01/2023	WVA Assessment Amount <u>per dose</u> from 07/01/2023 to 06/30/2024	Percent Change 07/01/2022 to 07/01/2023
Hepatitis A							
90633	58160-0825-52 (10 pack – 1 dose syringe)	Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use	Havrix®	\$20.72	\$36.92	\$22.79	10.0%
	00006-4095-02 (10 pack – 1 dose syringe)		Vaqta®		\$36.66		
Hepatitis B							
90744	00006-4981-00 (10 pack – 1 dose vial)	Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use	Recombivax HB®	\$12.54	\$26.35	\$13.79	10.0%
	00006-4093-02 (10 pack – 1 dose syringe)						
	58160-0820-52 (10 pack – 1 dose syringe)		Engerix B®		\$27.36		
Rotavirus							
90680	00006-4047-41 (10 pack – 1 dose tube) <b>ADDED: 00006-4047-20 (25 pack – 1 oral dose)</b>	Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use	RotaTeq®	\$72.04	\$93.19	\$79.24	10.0%
90681	58160-0854-52 (10 pack – 1 dose vial)	Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use	Rotarix®	\$97.88	\$134.72	\$107.67	10.0%
	58160-0740-21 (10 pack – 1 oral dose)				\$130.82		

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose from 07/01/2022 to 06/30/2023	For Reference: CDC Private Sector Cost/Dose 04/01/2023	WVA Assessment Amount per dose from 07/01/2023 to 06/30/2024	Percent Change 07/01/2022 to 07/01/2023
DTaP							
90696	58160-0812-52 (10 pack – 1 dose syringe)	Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use	Kinrix®	\$41.93	\$59.39	\$46.12	10.0%
	49281-0562-10 (10 pack – 1 dose vial)		Quadracel™		\$61.13		
	49281-0564-15 (10 pack – 1 dose syringe)						
90697	63361-0243-15 (10 pack – 1 dose syringe)	Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, Haemophilus b conjugate (meningococcal protein conjugate), and Hepatitis B (recombinant) vaccine	Vaxelis™	\$83.38	\$146.59	\$91.72	10.0%
	63361-0243-10 (10 pack – 1 dose vial)						
90698	49281-0511-05 (5 pack – 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use	Pentacel®	\$61.94	\$111.30	\$68.13	10.0%
90700	49281-0286-10 (10 pack – 1 dose vial)	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than seven years, for intramuscular use	Daptacel®	\$18.63	\$35.75	\$20.49	10.0%
	58160-0810-52 (10 pack – 1 dose syringe)		Infanrix®		\$28.02		
90702	49281-0225-10 (10 pack – 1 dose vial)	Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use	DT (pediatric)	\$59.59	N/A	\$65.55	10.0%
90723	58160-0811-52 (10 pack – 1 dose syringe)	Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use	Pediarix®	\$60.96	\$92.63	\$67.07	10.0%
Tdap							
90714	49281-0215-15 (10 pack – 1 dose syringe)	Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use	Tenivac®	\$16.42	\$39.74	\$18.06	10.0%
	49281-0215-10 (10 pack – 1 dose vial)				TDVAX™		
	13533-0131-01 (10 pack – 1 dose vial)	Tetanus and diphtheria toxoids (Td) adsorbed when administered to individuals 7 years or older, for intramuscular use					

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose from 07/01/2022 to 06/30/2023	For Reference: CDC Private Sector Cost/Dose 04/01/2023	WVA Assessment Amount per dose from 07/01/2023 to 06/30/2024	Percent Change 07/01/2022 to 07/01/2023
90715	58160-0842-11 (10 pack – 1 dose vial)	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use	Boostrix®	\$32.73	\$46.08	\$36.00	10.0%
	58160-0842-52 (10 pack – 1 dose syringe)						
	49281-0400-10 (10 pack – 1 dose vial)		Adacel®		\$52.41		
	49281-0400-20 (5 pack – 1 dose syringe)				\$52.41		
Haemophilus influenzae							
90647	00006-4897-00 (10 pack – 1 dose vial)	Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use	PedvaxHIB®	\$13.54	\$28.87	\$14.89	10.0%
90648	49281-0545-03 (5 pack – 1 dose vial)	Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use	ActHIB®	\$9.46	\$18.94	\$10.41	10.0%
	58160-0818-11 (10 pack – 1 dose vial)		Hiberix®		\$12.45		
Pneumococcal							
90670	00005-1971-02 (10 pack – 1 dose syringe)	Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use	Prevnar 13™	\$144.84	\$226.43	\$159.32	10.0%
Note: Prevnar 20 is expected to be on the market by fall 2023. The CPT and NDC codes will be updated then. The WVA Grid Amount is the same as Prevnar 13.							
CPT TBD	NDC TBD (Presentation TBD)	Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use	Prevnar 20™	N/A	TBD	\$159.32	
90671	00006-4329-03 (10 pack – 1 dose syringe)	Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF	Vaxneuvance™	\$165.52	\$216.09	\$182.07	10.0%
90732	00006-4837-03 (10 pack – 1 dose syringe)	Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use	Pneumovax® 23	\$59.78	\$117.08	\$65.76	10.0%
Inactivated Poliovirus							
90713	49281-0860-10 (10 dose vial)	Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use	IPOL®	\$13.90	\$40.64	\$15.29	10.0%

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose from 07/01/2022 to 06/30/2023	For Reference: CDC Private Sector Cost/Dose 04/01/2023	WVA Assessment Amount per dose from 07/01/2023 to 06/30/2024	Percent Change 07/01/2022 to 07/01/2023
<b>MMR</b>							
90707	00006-4681-00 (10 pack – 1 dose vial)	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use	M-M-R® II	\$21.77	\$89.87	\$23.95	10.0%
	58160-0824-15 (10 pack – 1 dose vial)		Priorix	\$24.14		\$23.95	-0.8%
90710	00006-4171-00 (10 pack – 1 dose vial)	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use	ProQuad®	\$138.67	\$262.37	\$152.54	10.0%
<b>Varicella</b>							
90716	00006-4827-00 (10 pack – 1 dose vial)	Varicella virus vaccine (VAR), live, for subcutaneous use	Varivax®	\$110.28	\$159.99	\$121.31	10.0%
<b>HPV</b>							
90651	00006-4121-02 (10 pack – 1 dose syringe)	Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use	Gardasil®9	\$189.08	\$268.77	\$207.99	10.0%
<b>Meningococcal B</b>							
90620	58160-0976-20 (10 pack – 1 dose syringe)	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use	Bexsero®	\$120.84	\$211.32	\$132.92	10.0%
90621	00005-0100-10 (10 pack – 1 dose syringe)	Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use	Trumenba®	\$115.17	\$179.70	\$126.69	10.0%
<b>Meningococcal Conjugate</b>							
90619	49281-0590-05 (5 pack – 1 dose vial)	Meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine .5mL dose, preservative free	MenQuadfi™	\$96.15	\$156.11	\$105.77	10.0%
90734	49281-0589-05 (5 pack – 1 dose vial)	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135, quadrivalent (MCV4 or MenACWY), for intramuscular use	Menactra®	\$96.15	\$141.70	\$105.77	10.0%
	58160-0955-09 (5 pack – 1 dose vial)		Menveo®		\$148.49		

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose from 07/01/2022 to 06/30/2023	For Reference: CDC Private Sector Cost/Dose 04/01/2023	WVA Assessment Amount per dose from 07/01/2023 to 06/30/2024	Percent Change 07/01/2022 to 07/01/2023
<b>Influenza</b>							
90672	66019-0310-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent	\$18.88	\$23.75	\$20.77	10.0%
90674	70461-0323-03 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent	\$16.02	\$30.10	\$17.62	10.0%
90686	19515-0814-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent	\$13.50	\$19.73	\$14.85	10.0%
	49281-0423-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR		\$19.76		
90688	49281-0639-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV	\$13.55	\$18.44	\$14.91	10.0%

**NOTE: The WVA reserves the right to modify the Assessment Grid in effect at any time with Board approval and appropriate notification of payers.**

To ensure proper DBA submission and carrier/TPA remittance to the WVA, providers should check the:

- **Date of service** to ensure the correct Grid year is being used;
- **CPT code** to ensure it is a valid code (\*see note below); and
- **Assessment amount** to ensure proper DBA submission and carrier/TPA remittance to the WVA.

\*Please note: Sometimes vaccine material is still viable and can be administered, even if it has been discontinued from prior Grids and is not shown on the current Grid.

If the CPT code is not offered on the current Grid, providers should check the legacy information at the end of the grid document to determine if a prior Grid amount should be billed on the DBA. Please validate the date of service and the legacy Grid year when selecting the Grid amount.

**DISCONTINUED PEDIATRIC INFLUENZA NDC CODES AS OF JUNE 30, 2023**

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename
90686	19515-0808-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent
	49281-0422-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR
90688	49281-0637-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV
90672	66019-0309-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent
90674	70461-0322-03 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent

**DISCONTINUED PEDIATRIC INFLUENZA NDC CODES AS OF JUNE 30, 2022**

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename
90686	19515-0818-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent
	49281-0421-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR
90688	49281-0635-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV
90672	66019-0308-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent
90674	70461-0321-03 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent



**DISCONTINUED PEDIATRIC INFLUENZA NDC CODES AS OF JUNE 30, 2021**

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename
90686	19515-0816-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent
	49281-0420-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR
90688	49281-0635-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV
90672	66019-0308-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent
90674	70461-0321-03 (10 pack - 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent

**DISCONTINUED PEDIATRIC INFLUENZA NDC CODES AS OF JUNE 30, 2020**

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename
90686	19515-0906-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent
	49281-0419-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR
90672	66019-0306-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent
90688	49281-0631-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV
90674	70461-0319-03 (10 pack - 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent

DISCONTINUED CPT OR NDC CODES FROM JULY 1, 2022 ASSESSMENT GRID				
CPT Code	NDC Code / Packaging	July 1, 2022 Grid CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2022
NONE				N/A

DISCONTINUED CPT OR NDC CODES FROM JULY 1, 2020 ASSESSMENT GRID				
CPT Code	NDC Code / Packaging	July 1, 2021 Grid CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2021
90696	58160-0812-11 (10 pack – 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use	Kinrix®	\$41.93
90698	49281-0510-05 (5 pack – 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use	Pentacel®	\$61.94
90700	58160-0810-11 (10 pack – 1 dose vial)	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than seven years, for intramuscular use	Infanrix®	\$18.63

DISCONTINUED CPT OR NDC CODES FROM JULY 1, 2019 ASSESSMENT GRID				
CPT Code	NDC Code / Packaging	July 1, 2019 Grid CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2019
90636	58160-0815-52 (10 pack – 1 dose syringe)	Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use.  (Age 18 only for CVP)	Twinrix®	\$67.29

DISCONTINUED CPT OR NDC CODES FROM JULY 1, 2018 ASSESSMENT GRID				
CPT Code	NDC Code / Packaging	CPT Code Description July 1, 2018 Grid	Tradename	WVA Assessment Amount per dose as of 7/1/2018
90685	49281-0518-25 (10 pack - 1 dose syringe)	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6 - 35 months of age, for intramuscular use (Code Price is per 0.25 mL dose)	Fluzone Pediatric Preservative Free (PF)	\$23.16

DISCONTINUED CPT OR NDC CODES FROM JULY 1, 2017 ASSESSMENT GRID				
CPT Code	NDC Code	CPT Code Description July 1, 2017 Grid	Trade Name(s)	WVA Assessment Amount per dose as of 7/1/2017
90644	58160-0801-11	Meningococcal conjugate vaccine, serogroups C & Y and Hemophilus influenza B vaccine (Hb-MenCY), 4 dose schedule, when administered to high risk children 2 - 15 months of age, for intramuscular use	MenHibrix	\$14.72
90649	00006-4045-41	Human Papilloma Virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Gardasil	n/a
90650	58160-0830-52	Human Papilloma virus (HPV) vaccine, types 16, 18, bivalent, 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Cervarix	n/a
90743	00006-4981-00	Hepatitis B vaccine, adolescent dosage (2-dose schedule), for intramuscular use (Code price is per dose) (Recombivax HB 10mcg = one dose)	Recombivax HB	\$17.19
90685	49281-0517-25	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6 - 35 months of age, for intramuscular use (Code Price is per 0.25 mL dose)	Fluzone Pediatric Preservative Free (PF)	\$23.16
90687	49281-0517-25	Influenza virus vaccine, quadrivalent, split virus, when administered to children 6-35 months of age, for intramuscular use	Fluzone	\$18.47



*Ensuring Funds for Childhood Vaccines*

# Provider Billing Improvement Plan Discussion

Presented to the  
Washington Vaccine Association  
Operations Committee Meeting  
April 25, 2023

Confidential and Proprietary © 2023



# Provider Billing Improvement Plan Steps

## DRAFT for Discussion

